{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:08:33Z","timestamp":1792112913209,"version":"4.4.0"},"reference-count":56,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Faculte de Pharmacie, Universite de Montreal","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100004734","name":"Jewish General Hospital","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004734","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Cross-sectional study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>The psychiatry unit of a Canadian tertiary care teaching hospital in Montreal, Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>402 patients with aforementioned disorders who initiated, restarted or switched to one of the following antipsychotics: clozapine, olanzapine, risperidone, paliperidone or quetiapine, between 2013 and 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary outcome measures<\/jats:title><jats:p>We assessed the proportion of cardiometabolic parameters monitored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Secondary outcome measures<\/jats:title><jats:p>We identified predictors that influence the monitoring of cardiometabolic parameters and we assessed the proportion of adequate interventions following the screening of uncontrolled blood pressure and fasting glucose or glycated haemoglobin (HbA1c) results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Only 37.3% of patients received monitoring for at least three cardiometabolic parameters. Blood pressure was assessed in 99.8% of patients; lipid profile in 24.4%; fasting glucose or HbA1c in 33.3% and weight or body mass index in 97.8% of patients while waist circumference was assessed in 4.5% of patients. For patients with abnormal blood pressure and glycaemic values, 42.3% and 41.2% subsequent interventions were done, respectively. The study highlighted the psychiatric diagnosis (substance induced disorder OR 0.06 95% CI 0.00 to 0.44), the presence of a court-ordered treatment (OR 0.79 95% CI 0.35 to 1.79) and the treating psychiatrist (up to OR 34.0 95% CI 16.2 to 140.7) as predictors of cardiometabolic monitoring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study reports suboptimal baseline cardiometabolic monitoring of patients taking an antipsychotic in a Canadian hospital. Optimising collaboration within a multidisciplinary team may increase cardiometabolic monitoring.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2021-055454","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T17:28:14Z","timestamp":1649784494000},"page":"e055454","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study \u2013 a cross-sectional study"],"prefix":"10.1136","volume":"12","author":[{"given":"Jennifer","family":"Fontaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rainone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Wazzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmella","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Rej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lordkipanidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-857X","authenticated-orcid":false,"given":"Vincent","family":"Dagenais-Beaul\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"2022051704410762000_12.4.e055454.1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Guidelines for the pharmacotherapy of schizophrenia in adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can J Psychiatry"},{"key":"2022051704410762000_12.4.e055454.2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and International Society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"2022051704410762000_12.4.e055454.3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-Generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","author":"Hirsch","year":"2017","journal-title":"Drug Saf"},{"key":"2022051704410762000_12.4.e055454.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1227"},{"key":"2022051704410762000_12.4.e055454.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008779"},{"key":"2022051704410762000_12.4.e055454.6","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2012.28"},{"key":"2022051704410762000_12.4.e055454.7","first-page":"15","article-title":"Hyperglycemia and antipsychotic medications","volume":"62 Suppl 27","author":"Haupt","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"2022051704410762000_12.4.e055454.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01158.x"},{"key":"2022051704410762000_12.4.e055454.9","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712001241"},{"key":"2022051704410762000_12.4.e055454.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00234.x"},{"key":"2022051704410762000_12.4.e055454.11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.4088\/JCP.v67n0704","article-title":"Associations between bipolar disorder and metabolic syndrome: a review","volume":"67","author":"Taylor","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"2022051704410762000_12.4.e055454.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00520.x"},{"key":"2022051704410762000_12.4.e055454.13","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4088\/JCP.14r09635","article-title":"Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis","volume":"76","author":"Vancampfort","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"2022051704410762000_12.4.e055454.14","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20420"},{"key":"2022051704410762000_12.4.e055454.15","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291714000634"},{"key":"2022051704410762000_12.4.e055454.16","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.4088\/JCP.16m10976","article-title":"Long-Term antipsychotic use and major cardiovascular events: a retrospective cohort study","volume":"78","author":"Szmulewicz","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"2022051704410762000_12.4.e055454.17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2016.16040442","article-title":"Endogenous and Antipsychotic-Related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study","volume":"174","author":"Rajkumar","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2022051704410762000_12.4.e055454.18","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0707"},{"key":"2022051704410762000_12.4.e055454.19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-Year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"2022051704410762000_12.4.e055454.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1848-y","article-title":"Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews","volume":"18","author":"Ijaz","year":"2018","journal-title":"BMC Psychiatry"},{"key":"2022051704410762000_12.4.e055454.21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/NDT.S100846","article-title":"Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review","volume":"12","author":"Fornaro","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2022051704410762000_12.4.e055454.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.03.018"},{"key":"2022051704410762000_12.4.e055454.23","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.2.596"},{"key":"2022051704410762000_12.4.e055454.24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jcjd.2013.01.009","article-title":"Canadian diabetes association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction","volume":"37 Suppl 1","author":"Cheng","year":"2013","journal-title":"Can J Diabetes"},{"key":"2022051704410762000_12.4.e055454.25","doi-asserted-by":"publisher","DOI":"10.1017\/S003329171100105X"},{"key":"2022051704410762000_12.4.e055454.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"2022051704410762000_12.4.e055454.27","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000142282.62336.e9"},{"key":"2022051704410762000_12.4.e055454.28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1192\/pb.bp.114.048793","article-title":"Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression","volume":"39","author":"Loebel","year":"2015","journal-title":"BJPsych Bull"},{"key":"2022051704410762000_12.4.e055454.29","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S117321"},{"key":"2022051704410762000_12.4.e055454.30","unstructured":"Dagenais-Beaul\u00e9 V , Rafizadeh R , Zhou T . Antipsychotics. In: Procyshyn R , Jeffries JJ , eds. Clinical Handbook of psychotropic drugs. 24th ed. Boston: Hogrefe, 2021."},{"key":"2022051704410762000_12.4.e055454.31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"2022051704410762000_12.4.e055454.32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2022051704410762000_12.4.e055454.33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","article-title":"Second-Generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects","volume":"41","author":"Rognoni","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2022051704410762000_12.4.e055454.34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04392"},{"key":"2022051704410762000_12.4.e055454.35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","article-title":"Comparative pharmacology of risperidone and paliperidone","volume":"15","author":"Corena-McLeod","year":"2015","journal-title":"Drugs R D"},{"key":"2022051704410762000_12.4.e055454.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.01.005"},{"key":"2022051704410762000_12.4.e055454.37","doi-asserted-by":"publisher","DOI":"10.1177\/1039856215604484"},{"key":"2022051704410762000_12.4.e055454.38","doi-asserted-by":"publisher","DOI":"10.1.1.35.7574"},{"key":"2022051704410762000_12.4.e055454.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-9868.2005.00503.x"},{"key":"2022051704410762000_12.4.e055454.40","first-page":"137","article-title":"Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting","volume":"9","author":"Ghate","year":"2012","journal-title":"Ment Health Fam Med"},{"key":"2022051704410762000_12.4.e055454.41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-80"},{"key":"2022051704410762000_12.4.e055454.42","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.002542012"},{"key":"2022051704410762000_12.4.e055454.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.08.012"},{"key":"2022051704410762000_12.4.e055454.44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109506"},{"key":"2022051704410762000_12.4.e055454.45","doi-asserted-by":"publisher","DOI":"10.2190\/PM.40.2.g"},{"key":"2022051704410762000_12.4.e055454.46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2215-0366(19)30414-6","article-title":"Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people","volume":"7","author":"Solmi","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2022051704410762000_12.4.e055454.47","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.16m02017","article-title":"Cardiometabolic assessment, diagnosis, and treatment of chronic medical illnesses during an inpatient psychiatric hospitalization: colocated medical care versus treatment as usual","volume":"18","author":"Tatreau","year":"2016","journal-title":"Prim Care Companion CNS Disord"},{"key":"2022051704410762000_12.4.e055454.48","doi-asserted-by":"publisher","DOI":"10.4103\/2152-7806.139612"},{"key":"2022051704410762000_12.4.e055454.49","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/inm.12327","article-title":"Impact of a nurse practitioner role on metabolic monitoring completion and referrals for consumers admitted to the intensive care area of an acute inpatient psychiatric unit","volume":"27","author":"Brown","year":"2018","journal-title":"Int J Ment Health Nurs"},{"key":"2022051704410762000_12.4.e055454.50","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240204"},{"key":"2022051704410762000_12.4.e055454.51","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/ajhp\/61.24.2672","article-title":"Pharmacist interventions to improve the management of coronary artery disease","volume":"61","author":"Chapman","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"2022051704410762000_12.4.e055454.52","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.6.586"},{"key":"2022051704410762000_12.4.e055454.53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjquality.u211816.w4748","article-title":"Utilizing clinical pharmacists to improve delivery of evidence-based care for depression and anxiety in primary care","volume":"5","author":"Locke","year":"2016","journal-title":"BMJ Qual Improv Rep"},{"key":"2022051704410762000_12.4.e055454.54","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1592\/phco.29.8.975","article-title":"Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents","volume":"29","author":"Schneiderhan","year":"2009","journal-title":"Pharmacotherapy"},{"key":"2022051704410762000_12.4.e055454.55","unstructured":"Canadian Pharmacist Association . Pharmacists' expanded scope of practice in Canada 2019, 2019. Available: https:\/\/www.pharmacists.ca\/pharmacy-in-canada\/scope-of-practice-canada\/ [Accessed cited 2019 June 15]."},{"key":"2022051704410762000_12.4.e055454.56","unstructured":"Centers for Disease Control and Prevention . Collaborative Practice Agreements and Pharmacists\u2019 Patient Care Services - A Ressource for Pharmacicists Atlanta: US Dept. of Health and Human Services, Centers for Disease Control and Prevention, 2013. Available: https:\/\/www.cdc.gov\/dhdsp\/pubs\/docs\/translational_tools_pharmacists.pdf"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-055454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T11:47:46Z","timestamp":1652788066000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-055454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/bmjopen-2021-055454"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-055454","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}